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Abstract
This review article focuses on the various aspects of translational research, where research on
human subjects can ultimately enhance the diagnosis and treatment of future patients. While we
will use specific examples relating to the asbestos related cancer mesothelioma, it should be
stressed that the general approach outlined throughout this review is readily applicable to other
diseases with an underlying molecular basis. Through the integration of molecular-based
technologies, systematic tissue procurement and medical informatics, we now have the ability to
identify clinically applicable "genotype"-"phenotype" associations across cohorts of patients that can
rapidly be translated into useful diagnostic and treatment strategies. This review will touch on the
various steps in the translational pipeline, and highlight some of the most essential elements as well
as possible roadblocks that can impact success of the program. Critical issues with regard to
Institutional Review Board (IRB) and Health Insurance Portability and Accountability Act (HIPAA)
compliance, data standardization, sample procurement, quality control (QC), quality assurance
(QA), data analysis, preclinical models and clinical trials are addressed. The various facets of the
translational pipeline have been incorporated into a fully integrated computational system,
appropriately named Dx2Tx. This system readily allows for the identification of new diagnostic
tests, the discovery of biomarkers and drugable targets, and prediction of optimal treatments based
upon the underlying molecular basis of the disease.
The Ultimate Goal
Our systematic approach to translational medicine has
been designed to achieve a vision shared by numerous
"ambitious" investigators who are focused on applying
bench-side discoveries to the clinical setting (Figure 1).
We share a vision of future medicine, in which it will be
possible to predict the likelihood (risk) of a clinical event
during the course of an individual's lifetime, accurately
diagnose the event in its earliest manifestation, and treat
accordingly based upon the diagnosis. We believe that
this will become reality through the combination of med-
ical informatics and the multiplex "omics" technologies
(that we broadly characterize as genomics and proteomics
throughout this review) now at our disposal. Clearly,
there are certain bioethical, political and fiscal roadblocks
which need to be considered as we progress towards this
goal, not limited to patient privacy, regulatory issues,
health care reimbursement and ownership of intellectual
property. In this review however, we will focus on the
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science and logistics relating to implementation of a suc-
cessful translational research program.
While a degree of project specificity must be incorporated
into the design of any research effort, many of the compo-
nents of translational research are shared across appar-
ently disparate disease areas (Figure 2). Although many
facets of a research proposal (i.e. attaining funding and
IRB approval) require specification of the particular
hypothesis under evaluation, we also make every effort to
collect samples (such as blood, urine and tissue) together
with as much clinical data (both historical and longitudi-
nal) as possible while maintaining patient confidentiality,
privacy and safety at the forefront. In addition to testing
the pre-conceived clinical hypothesis (for example, does
an event have an underlying molecular basis), this
approach readily allows for the discovery of additional
genotype-phenotype patterns (hypotheses) that can be
subsequently cross-validated in additional subjects and
samples (i.e. this event does have an underlying molecu-
lar basis). This somewhat blinded yet methodical
approach clearly requires a database and supporting ana-
lytical software that are intricately linked, such that analyt-
ical results can become a new query against the database
content (Figure 3). While these aspects of the Dx2Tx sys-
tem will be discussed in more detail throughout this
review, it is essential to stress the importance of collecting
and archiving standardized clinical data throughout the
course of a patient's lifespan. It is difficult to identify sta-
tistically significant correlations within non-standardized
datasets. Well documented clinical data is equally as
important as clinical samples, a fact often overlooked in
many research studies reported to date.
Effective translational research requires a multi-discipli-
nary and team approach. Our initial concept meetings
include HIPAA/IRB advisors, research nurses, surgeons
(and/or other health care providers such as oncologists),
pathologists and members of diagnostic service labs,
information technologists (both biological and medical
disciplines) and statisticians in addition to the principal
investigators. Each member of the translational research
The goal of our translational research effort – From Diagnosis to Treatment (Dx2Tx)Figure 1
The goal of our translational research effort – From Diagnosis to Treatment (Dx2Tx). We have developed a systems approach 
to track pertinent clinical events within the lifespan of an individual subject. In the future, it may be possible to predict the risk 
of a clinical event in advance, accurately diagnose the event in its earliest manifestations, and treat based upon the underlying 
molecular/clinical traits. We believe the integration of medical informatics with cutting edge molecular technologies such as 
genomics and proteomics will expedite this transition to molecular-based medicine.
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team is critical to the overall productivity and success of
the pipeline. In acknowledgement of the effectiveness of
this approach, we would advise other establishments to
involve key personnel across the various disciplines early.
We also believe that smaller dedicated teams can often be
more efficient and less bureaucratic than oversized
consortium.
IRB, HIPAA, Scheduling and Consenting
The development of research protocols on human sub-
jects that involve specimen and/or data collection must be
approved by the investigational review boards (IRB). The
IRB governs patient safety and risk for the hospitals and/
or universities/institutions. In accordance with federal
regulations, one of the requirements states that each
human subject must be thoroughly informed about the
research to be undertaken on their sample and/or data
during a consenting process. The specificity of the consent
should be such that it outlines the research protocol, study
procedures and risks and benefits and meets the federal,
state and local requirements, so that the subject can make
an informed decision regarding participation in the study.
In retrospect, a well informed patient can help facilitate
the procurement of clinical data and samples in an effi-
cient and longitudinal manner.
While the typical testing of a hypothesis requires the col-
lection of only a subset of the available clinical data (for
example tumor stage, survival time), the emerging field of
medical informatics and electronic charts allows for the
potential collection of vast quantities of standardized clin-
ical data that potentially harbors invaluable information
Systematic overview of translational researchFigure 2
Systematic overview of translational research. Commencing with human research subjects, we can transition through specimen 
and data collection, data analysis, preclinical models and ultimately clinical trails. The various facets of this pipeline will be dis-
cussed throughout this review.
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The Dx2Tx integrated solution stores and analyzes clinical (and preclinical), experimental and molecular data from a variety of disparate sourcesFigu e 3
The Dx2Tx integrated solution stores and analyzes clinical (and preclinical), experimental and molecular data from a variety of 
disparate sources. For more information see http://www.vai.org/vari/xenobase/summary.asp
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with regard to additional "traits" or "phenotypes". As
such, we currently collect upward of 9000 potential data
fields per patient within our specific IRB-approved proto-
cols, all of which can be populated during the normal
course of patient care and stored within either electronic
or paper records for each subject. In addition, each patient
receives a standardized self-reporting questionnaire
addressing histories (such as habits, family history, medi-
cation history, etc). Any protected fields are restricted
through a security portal, which can be considered a suit-
able clinical gatekeeper (such as research nurse or elec-
tronic portal) (Figure 2). This security portal allows the
flow of clinical data to the laboratory researcher as defined
in the IRB-approved protocol, and also links each subject/
sample with an anonymous ID. Patient data that is de-
identified in this fashion is not subject to HIPAA
regulations. It should be noted that some protected health
information (such as zip code) may represent valuable
information to the research team (for example when
addressing potential local or regional causes of disease
incidence). Patients are informed and provide written
authorization for the inclusion of such potential identifi-
ers during the consenting process; these are then collected
and archived in secure locations. For example, we rou-
tinely include current home and work 5-digit ZIP codes
and date of birth in our IRB-approved protocols. The latter
is used to normalize patients based upon age of each clin-
ical event, where date of birth represents time zero in a
patient's life span. As such, every recorded event in a
patient's life is tagged to a date and time, such that events
can be readily interrelated. For more information on
HIPPA and sharing of PHI for research purposes, see http:/
/www.hhs.gov/ocr/hipaa.
In addition to IRB and HIPAA issues, patient recruitment
can also be a major hurdle. The teamwork approach is
critical here, together with patient/physician outreach and
screening efforts as necessary. Our experience is the vast
majority of patients are enthusiastic about inclusion in
research studies so long as they are informed of the oppor-
tunity, particularly since we are careful to follow standard-
of-care. For the most part, we are finding a willingness to
participate for the hope of betterment for the whole,
whether it is potentially helping their own families or oth-
ers with their disease. At this level, the physician is the
central figure and is uniquely positioned to introduce the
protocol and support patient participation in the study.
For studies where low participation is expected (predom-
inantly due to low incidence), we typically include an IRB-
approved public educational effort (for both physicians
and potential patients) that maximizes recruitment. Our
clinical research nurses work closely with the physician(s)
and their office scheduling staff for notification of poten-
tial candidates in advance wherever possible. This team
approach with the physician advocating the effort allows
the greatest accrual particularly when there are several
geographic sites for meeting potential protocol volun-
teers. On site consenting of high risk or suspected individ-
uals within the outpatient clinic and hospital settings
where these patients are typically evaluated should to be
considered to enhance accrual. For patients with known
disease, the best environment for accrual occurs in a
multidisciplinary setting in which the key physician works
closely with the medical oncologist, radiation oncologist,
nurses, physician assistants, residents and research staff.
This is particularly important for longitudinal sampling of
patients on treatment protocols to minimize the loss of
follow-up data. The logistics of a coordinated approach
may differ between a university medical school setting
and a community based practice due to the competing
obligations of a busy private practice. The multidiscipli-
nary approach is optimal in a single setting in which
patients can be seen by the various disciplines, thereby,
reducing the extent of patient relocation between specialty
offices and allowing for centralized specimen and data
collection. Nonetheless, in community-based practice, we
have introduced standardized mechanisms allowing us to
consent patients and collect clinical samples and data
from multiple sites.
Clinical Data Acquisition
There are now abundant examples where clinical research-
ers are using the revolutionary "omics" technologies to
demonstrate a clear association between the molecular
make-up ("genotype") of clinical samples and well-
defined clinical characteristics ("phenotype"). Near-com-
plete genotypes can now be obtained through multiplex
technologies such as sequencing, mutational screening
(such as single nucleotide polymorphism (SNP) analysis)
and gene/protein expression profiling. The absence of
well annotated clinical information (such as medications,
response to treatments, histories, environmental expo-
sures, toxicities, etc), however, is evident from most stud-
ies reported to date. Rather than taking the reductionist
approach at the time of data collection, our group instead
chooses to gather all information relating to an individ-
ual's medical history as well as follow-up data as it
becomes available and as approved by the IRB. It is rela-
tively trivial to reduce the clinical data pool retrospectively
during analysis as deemed necessary. Our Dx2Tx system
date/time stamps individual events for a given subject/
sample, such that multiple events can be temporally asso-
ciated. The first step is to gather the information in its
rawest form from a standardized source. This could be as
complicated as a centralized medical informatics database
(such as the Oracle-based clinical informatics system used
by Spectrum Health Hospitals (Grand Rapids, Michigan)
housing rich longitudinal clinical data that can be
expressed in Health Level 7 standards for data portabil-
ity), or it could be as uncomplicated as a locally
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maintained excel spreadsheet or access database. Regard-
less of the source, we attempt to collect as much informa-
tion regarding a subject's history, diagnosis, treatment,
and response assessment as possible. As highlighted
above, the critical elements are reliability of the source
data and standardization. While we do perform statistical
analysis on parsed text from open string comments, we
attempt to force objective measurements (such as integers,
floating numbers, text pull downs, binary data, etc) wher-
ever feasible. In the absence of a centralized clinical data-
base utilizing standardized clinical nomenclature and
data, the responsibility falls on the clinical members of
the team to interpret clinical data within isolated data-
bases and/or paper charts. Clearly, the navigation from
paper to electronic medical records, and the generation of
middleware that can link disparate databases, will greatly
alleviate this burden that rapidly becomes a major rate-
limiting step in the translational pipeline. Coupled with
voice recognition and electronic data recording with
inbuilt QC check-points, standardized digital data entry
should become the norm in the not so distant future.
Clinical data permitted under protocol should be, where
possible, prospectively accumulated. The accuracy of the
data, particularly those parameters such as the pathologic
characteristics, clinical staging, dates of intervention,
dates of intermediate endpoints (such as disease progres-
sion or death), must be unquestionable in order to iden-
tify clinical and molecular correlations among diverse
datasets. The accuracy of these data will depend to a large
extent upon the frequency of follow-up for parameters
such as disease progression, and the degree to which the
patients' status is investigated longitudinally. Patients on
clinical trials, where the procedures and follow-up are
specified as part of the protocol, will have the most robust
and standardized data since interval radiographic and
physical examinations and/or other clinical procedures
and methods of data collection must be adhered to in
order to avoid protocol violation. Moreover, the approach
of the physician(s) who follows the patient and the avail-
ability of an existing mechanism that readily allows the
retrieval of prospective data (i.e. a database) will greatly
influence the accuracy of the data. Within oncology, stag-
ing issues are some of the more difficult to resolve, espe-
cially if inadequate staging is performed in the operating
room (OR) or if one must rely entirely on clinical or radi-
ographic data. For the majority of organ systems, the
oncological staging system is specified in the AJCC Staging
Handbook, but it is the responsibility of the investigator
to know whether the pathologic and intraoperative details
necessary for accurate staging were adequately performed.
These include but are not limited to accurate size measure-
ment of the primary tumor, careful intraoperative descrip-
tion of abutment or invasion of nearby structures,
verification of negative margins, and extent of lymph
node involvement. The patients used in the examples
below were all part of either Phase II or Phase III mesothe-
lioma protocols, with computerized tomographic surveil-
lance after surgery every 3–4 months until death. As such,
the accuracy of the clinical data was optimized. One sur-
geon performed the operations, obtained aggressive intra-
operative staging in all cases, and took the responsibility
for collecting samples and data from all participants in the
study. This approach led to the development of a consist-
ent standard of care philosophy for the surgical manage-
ment of mesothelioma.
Our Dx2Tx system performs detailed statistical analysis
on both clinical and molecular data, thus leaving little
room for error when it comes to standardized data collec-
tion and entry. Physicians are uniquely positioned to
organize the various aspects of data collection. This
endeavor begins with the design of a clinical protocol for
the procurement of specimens and the collection of data
from a patient population. In addition to identifying the
experimental group of patients (i.e. those with a condi-
tion or trait of interest), it is important to ensure the
inclusion of the proper control populations wherever pos-
sible. With respect to our mesothelioma protocols, the
correct controls for early diagnostic strategies include age-
matched individuals exposed to similar doses of asbestos
in order to compare with equivalent individuals diag-
nosed with the established disease. The recruitment of
these control subjects ideally begins in parallel with the
recruitment of the experimental group. In the absence of
the correct control group, the investigator must identify
cohorts of individuals within existing cooperative group
mechanisms, SPORES, or the Early Detection Research
Network (EDRN). In order to circumvent this problem,
the Karmanos Cancer Institute has established a National
Center for Vermiculite and Asbestos Related Cancers
through a cooperative clinical trial with the Center for
Environmental Medicine in Southeast Michigan. This
center, under informed consent, evaluates individuals
who have been exposed to asbestos in the workplace or at
home, and depending on history and pulmonary function
data, these individuals undergo computerized tomo-
graphic scanning to establish a baseline radiographic eval-
uation of asbestos exposure and risk. These individuals
also give written permission for periodic sample collec-
tion including blood and urine for studies of marker
assessment for asbestos related malignancies.
A major focus of our research is to identify the molecular
causes of differential therapeutic response across patient
populations (pharmacogenetics). It is generally appreci-
ated that patients and their disease show significant varia-
tions in response to a given treatment [1]. It is therefore
critical to develop standardized approaches for routinely
monitoring adverse responses (for example using
Journal of Translational Medicine 2004, 2:35 http://www.translational-medicine.com/content/2/1/35
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common toxicity criteria) as well as disease response (for
example using the Response Evaluation Criteria in Solid
Tumors, or RECIST criteria). While various reporting
schema are in place under specific clinical protocols, we
are working on a more systematic approach; the collection
of raw clinical data that can be compiled to assess clinical
response and toxicity. Accordingly, if the raw data is col-
lected, the response of all patients undergoing defined
treatments can be assessed in a longitudinal fashion. The
compiled response and toxicity data can then be analyzed
retrospectively with other clinical and molecular
attributes as outlined below.
Specimen Collection and Archiving
We have introduced standard procurement procedures for
various physiological samples including tissue, urine and
blood, all of which are now routinely collected under our
IRB-approved protocols. These have been optimized for
both ease and reliability of clinical collection as well as
maintaining the integrity of the sample for subsequent
histopathological and molecular analysis. DNA from
peripheral blood mononuclear lymphocytes (PBML)
obtained from whole blood can be screened by SNP anal-
ysis, to identify possible genetic markers of a clinical event
[2-4]. Once validated, these SNP markers could serve as a
genetic test to predict the risk of the event in prospective
subjects. Plasma or serum (we prefer non-clotted plasma)
and urine can be screened for proteomic markers of a clin-
ical incident, and used in future screening for diagnostic
purposes [5]. Per the approved protocol, tissue can be sub-
jected to a variety of DNA/RNA/Protein technologies, and
important diagnostic and therapeutic insight gained at the
molecular level [6]. It should be noted, that wherever pos-
sible, adjacent uninvolved "normal" tissue free of disease
should also be collected for comparison with the corre-
sponding diseased tissue. The example in this review will
focus on some published works [7] identifying diagnostic
and prognostic biomarkers in the tumor tissue of patients
with mesothelioma utilizing Affymetrix GeneChips for
assessing gene expression within the tissue. In this case,
we collected normal mesothelium of the peritoneum or
the pleura in conjunction with mesothelioma tumor
tissue.
The precise flow of the clinical sample from the patient to
the researcher will depend largely on the disease in ques-
tion and pre-existing departmental procedures. For exam-
ple, in a study of pancreatic cancer, urine is provided by
the patient prior to the procedure, since we have found
that intra-procedural catheterization can result in blood
contamination that effects subsequent proteomic analy-
sis. Blood is drawn from an IV access for collection of
plasma and PBML, while surgically resected tissue is snap
frozen on site (see below). However, a multiple myeloma
research protocol requires the collection of bone marrow
aspirates from both inpatient and outpatient clinics,
which are placed into tissue culture media and rapidly
transported on ice to the Flow Cytometry Molecular Diag-
nostic Laboratory for immunophenotyping and cytomet-
ric sorting of plasma cells. The sorted fraction is then
archived in freezing media for subsequent DNA, RNA
and/or protein analysis. Irrespective of procedure, it is
important to maintain a log book that tracks the flow of a
sample from the subject to freeze. Procurement time is
particularly important for RNA and some protein analysis,
since biomolecular degradation can be a significant factor.
Prior to collection, our procurement team (lab personnel
and research nurses) pre-label collection tubes and con-
tainers with anonymous identifier tags that are freezer
safe. Several kits that include equipment for blood draws,
urine collection and tissue procurement are preassembled
and made available to the research staff to ensure rapid
response for obtaining specimens. We have an on-call list
of several members for the research team who can reach
the pick-up point within 30 minutes of receiving a collec-
tion call. Through a coordinated multidisciplinary
approach, consenting and scheduling is typically obtained
well in advance in either the outpatient or inpatient
setting.
At the Karmanos Institute, we have found that the easiest
way to insure proper specimen harvest from patients with
solid tumors is for the surgeon to divide the specimen
directly in the OR and supervise its collection and distri-
bution to the laboratory for archiving. However at the Van
Andel Research Institute, we require oversight from the
Hospital Department of Pathology to release surgically
resected samples within the OR to the research team. The
critical issue is to ensure suitable material is harvested in
the correct fashion to allow accurate histopathological
diagnosis. In no way should the research effort impede
this quality-of-care. As a safety margin, we hold all frozen
tissue for a period of time until an official diagnosis has
been reported. In addition, wherever possible we embed
samples in OCT freezing media, and generate hematoxy-
lin/eosin (H/E)-stained histopathology slides for each
research sample. This not only provides high quality his-
topathology slides for possible diagnostic back-up, but
also allows us to correlate our molecular findings with the
histology of the same working sample. In addition to
entering pertinent data regarding the official diagnostic
pathology report, we have also developed standardized
report templates within Dx2Tx that accompany each
research sample, in which the pathological image is asso-
ciated with the corresponding data addressing critical var-
iables such as relative amount of each cell type, stage,
morphology etc. As with all data entered into Dx2Tx,
these metadata are directly amenable to subsequent statis-
tical analysis (see below).
Journal of Translational Medicine 2004, 2:35 http://www.translational-medicine.com/content/2/1/35
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At the time of resection, solid tissue samples are immedi-
ately frozen in either liquid nitrogen or, for sites with no
supply, a dry ice-chilled isopentane bath. Samples are
transported in aluminum foil, and stored at -80°C until
further processing. It should also be pointed out that
many of our protocols involve the collection of tissue
biopsies in addition to surgical resections. Since it is phys-
ically difficult to split a biopsy (although this is done for
example with bone marrow core biopsies), we typically
acquire additional samples beyond what are required for
accurate pathological diagnosis. If these additional sam-
ples are required by the research team, it is important to
disclose the supplementary procedures to the patient in
the informed consent. While obviously smaller in size
compared to surgical resections, we procure these speci-
mens as fresh tissue as described above. It is important to
note, some of our molecular technologies allow for the
use of as few as 500 cells for complete multiplex analysis.
Since biopsy material will doubtless be the predominant
source of tissue for future molecular-based diagnostics, it
is important to develop protocols to address smaller
sample size and possible mis-sampling issues. In addi-
tion, as a result of not restricting samples to excess surgical
specimens, biopsies can rapidly increase sample accrual
from larger cohorts of patients.
Urine and blood samples are transported on wet ice to the
research labs, while frozen tissue is transferred on dry ice.
Upon arrival in the laboratory, urine is typically divided
into suitably sized aliquots and frozen at -80°C. Blood is
fractionated into plasma or serum (again aliquoted and
frozen), while PBML are isolated by centrifugation and
Ficoll/Hipaque density gradient centrifugation and cryo-
genically frozen. Fresh frozen tissue specimens are
blocked in OCT if possible and stored at -80°C until
further use. All specimens are associated with the donat-
ing subject within Dx2Tx, and archived in a simple grid
system within dedicated and alarmed -80°C freezers. The
location and use of each aliquot is tracked within Dx2Tx
to readily allow for subsequent retrieval.
Sample Procurement – The "Omics"
The tissue collection protocols outlined above should be
evaluated for compatibility for the molecular analysis to
be performed. We typically perform SNP analysis on DNA
isolated from the PBML fraction of whole blood, gene
expression (mRNA) analysis on tissue, and proteomic
analysis of blood plasma/serum, urine and tissue. The
detailed discussion of each of these molecular protocols is
beyond the scope of this review (see [6] for a good starting
point of reference). There are important differences
between the various platforms available that can result in
some disparities in the results generated [8-10]. As such, it
is essential to document and ideally database protocols,
deviations from protocols (version control), and in
general, all experimental variables that could potentially
confound the results (for example see Minimum Informa-
tion About a Microarray Experiment http://
www.mged.org/Workgroups/MIAME). We enter these
variables into Dx2Tx in association with the correspond-
ing experimental procedure such that they can be ana-
lyzed together with the derived molecular and clinical
data. In this fashion, important QC and QA parameters
can be interrelated with molecular and clinical data.
Experiments that do not meet certain QC/QA criteria can
be excluded from the analysis if the data suggest that the
variable(s) is a major confounder. In this fashion, Dx2Tx
serves as an electronic notebook, the entries into which
can be routinely recorded and statistically analyzed. This
feature will be particularly important as potential applica-
tions advance towards clinical utility, for example through
ensuring compliance with the FDA and accrediting agen-
cies such as JACHO, CMS and CAP, and while maintain-
ing the necessary state, federal, and insurance applications
required to provide clinical diagnostic services.
Data Analysis
For so many investigators, analysis represents the "black
box" of the translational pipeline. It is reasonable to state
that statistical analysis of the data is one of the most
important steps in the translational process. In addition to
determining the sample size and inclusion/exclusion cri-
teria necessary to test a hypothesis, it is essential to utilize
the correct tests of statistical significance during both dis-
covery and application phases of the translational pipe-
line. This review will not detail all possible permutations
of biostatistics, but we will touch briefly on certain statis-
tical concepts. The average gene expression profiling
experiment can generate in excess of 30,000 individual
data points per clinical sample, while current high-
throughput SNP-chips can generate >100,000 discrete
attributes per analysis. Similarly, proteomic experiments
generate vast amounts of coupled data that includes both
fractionation (such as 2-D gels or 2-D liquid chromatog-
raphy) and detection (such as mass spectrometry) ele-
ments. Coupled with extensive clinical content, this
collectively presents significant challenges for data storage
and retrieval, as well as statistical analysis. The most fre-
quent frustration of new users of the "omics" technologies
remains "What are the data telling me?"
Before proceeding with specific examples, it is important
to grasp the concepts of normalization and data massag-
ing or "filtering" [11]. To compare data across multiple
samples, data is typically normalized or scaled such that
results from one experiment are directly comparable to
those of another. There are a number of methods to nor-
malization across experiments including the use of a com-
mon reference sample or internal controls such as
housekeeper genes/proteins that do not alter across
Journal of Translational Medicine 2004, 2:35 http://www.translational-medicine.com/content/2/1/35
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experiments. Various forms of mathematical normaliza-
tion can then be used (for example mean centering) to
scale the results across experiments. As discussed above,
through the tracking of protocols and minimizing experi-
mental variation, one can reduce the degree of scaling
required to directly compare data across different experi-
ments. The normalization routines, as with pre-filtering of
data, should be performed during an analysis session and
Sequential filtering of Affymetrix gene expression data to identify potential plasma biomarkers of mesotheliomaFig re 4
Sequential filtering of Affymetrix gene expression data to identify potential plasma biomarkers of mesothelioma. The key 
aspects of a disease biomarker include sensitivity and specificity. These can be partially addressed through logic-based filters 
within Dx2Tx.
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not prior to data entry, since the different normalization
and filtering routines can significantly effect the analytical
results. As such, it is important to track the normalization
and filtering criteria employed during analysis, such that
results from sessions using different methods can be com-
pared and contrasted.
One problem in dealing with vast amounts of clinical
and/or multiplexed molecular data from a relatively small
sample population is that many of the observed correla-
tions could (not necessarily do) occur by random chance.
One method investigators use to minimize the probability
of this so called "false discovery" is to reduce the
complexity of the data through successive rounds of filter-
ing. Depending on the application, we do use some filter-
ing under certain circumstances. However, as with
normalization, this is done during data analysis and not
prior to database entry. In this fashion, we can filter and
analyze the data "on the fly", allowing the user to evaluate
the effect of filtering the raw data. For example, if we were
looking for a specific set of genes that are found highly
expressed in mesothelioma relative to other tumor types,
we may eliminate genes in mesothelioma samples below
a certain expression (intensity) threshold, and those
above a certain level in other tumor types. This would
maximize the likelihood of identifying sensitive and spe-
cific mesothelioma genes, and minimize the gene pool
and hence probability of false discovery. We also use fold-
change filters depending on the application. For example,
we may only be interested in diagnostic biomarkers that
display at least a 4-fold increase in mesothelioma tumor
tissue relative to other tumor types and normal mesothe-
lium. In addition, genes with certain characteristics (such
as those that encode only secreted or transmembrane pro-
teins [12] can be filtered (included or excluded) within
Dx2Tx. Thus, while it is important to note that these filters
are not tests of statistical significance, they nonetheless
can be used in the context of biological logic, to maximize
the likelihood of identifying clinically valuable data
within multiplexed data. The logic flow depicted in Figure
4 shows the effect of successive rounds of filtering the data
from mesothelioma samples with the intent of identifying
possible biomarkers that may be detected in blood or
pleural effusions. This logic-based informatics approach
to identifying possible disease biomarkers in physiologi-
cal fluids can lead to candidate proteins that can be specif-
ically detected in the corresponding blood/urine samples
by other methods. We have shown the utility of this pre-
dictive approach in parallel with proteomic analysis of
plasma in some experimental models of cancer. While
this approach is yet to be validated in the human disease,
we believe that this represents an excellent supplement to
existing biomarker discovery programs that is readily
implemented through simple data filters.
There are an abundant number of methods that can be
employed during analysis of multiplex data to determine
statistical significance. In the absence of becoming a
quasi-expert in statistics, we highly recommend that the
assistance of any number of statisticians is sort. The key is
to understand why certain statistical tests are used under a
variety of circumstances, and what the limitations of each
test may be. We typically use similarity-based tests (such
as hierarchical clustering, principle component analysis,
multidimensional scaling, etc) to identify relationships
between variables (clinical, experimental and molecular)
within large datasets [13,14]. These metrics identify the
degree of similarity (or difference) between various
attributes, and are extremely powerful when attempting to
discover inter-sample relationships based upon their
molecular and/or clinical features. For example, unsuper-
vised hierarchical clustering can be used to cluster the X
attributes (such as mesothelioma samples) based upon
the values of the Y-attributes (such as relative gene expres-
sion) as shown in Figure 5. In addition, the Y attributes
can be clustered, based upon their similarity across the X
attributes, providing a 2-dimensional clustergram display-
ing overall relationships (Figure 6). The co-clustering of
samples is essentially a raw form of a molecular diagnostic
application since samples with similar genotypes cluster
based upon biological similarity (phenotypes). The co-
clustering of genes and/or clinical data is also a potentially
powerful application. For example, genes/proteins with
similar functionality are often co-regulated at the level of
their expression, and hence typically "co-cluster" on a
gene expression clustergram. This concept becomes partic-
ularly powerful when attempting to predict the function
of unknown genes based upon their overall correlation
with a gene of known functionality [15-17]. In the case of
clinical data, inter-relating clinical and/or environmental
events can also be performed. Hence, features that corre-
late (such as increased stage of disease and poor outcome)
are typically adjacent on the clustergram (Figure 7). Cou-
pled with the extensive collection of standardized clinical
data highlighted throughout this review, this feature alone
may have significant impact in the mining of clinical data
in disciplines such as epidemiology.
In addition to correlating clinical and molecular data indi-
vidually, these data types can be merged and viewed
simultaneously within the same clustergram. In this fash-
ion, possible associations between clinical, experimental
and molecular features can be readily identified. For
example, as shown in Figure 8, there appears to be an
association between T-stage and a number of genes
known to be involved regulation of the cell-cycle. Classi-
fication of gene/protein function (so called "annotation")
can provide important information with regards to the
underlying molecular cause(s) of a clinical event. In addi-
tion to utilizing the publicly available annotations (for
Journal of Translational Medicine 2004, 2:35 http://www.translational-medicine.com/content/2/1/35
Page 11 of 22
(page number not for citation purposes)
A two-color clustergram generated after hierarchical clustering of gene expression data (Affymetrix U95A) across 21 tumor samples colle ted f om patients with mesotheliomaFigur  5
A two-color clustergram generated after hierarchical clustering of gene expression data (Affymetrix U95A) across 21 tumor 
samples collected from patients with mesothelioma. Clustering has been performed in only the X axis, such that samples are 
grouped based upon similarity in overall gene expression (the identified sample sub-groups are color coded). The gene expres-
sion data has been mean centered, such that degrees of red and green indicate relatively high and low expression of the corre-
sponding gene respectively, while black represents the mean value across samples. In this fashion, the relative expression of 
many genes can be readily visualized across several samples simultaneously, and the relationships between samples observed.
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Hierarchical clustering of Affymetrix gene expression data as described in the legend to figure 5, with the exception that genes ar  also clustered based upon similarity in expression acros the samplesFigure 6
Hierarchical clustering of Affymetrix gene expression data as described in the legend to figure 5, with the exception that genes 
are also clustered based upon similarity in expression across the samples. In this fashion, correlations between samples and 
genes can be simultaneously observed.
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example see Gene Ontology http://www.geneontol
ogy.org), we also map results to molecular pathways using
detailed pathway mapping software now available. Taking
this approach, the coordinated expression of genes/pro-
teins can be seen to map to specific molecular networks,
therefore providing important information as to which
pathways maybe activated or in-activated in association
with a clinical event. For example, when all the genes dif-
ferentially expressed in recurrent mesotheliomas relative
to non-recurring tumors at a defined statistical signifi-
cance (p < 0.001) are mapped using the MetaCore™
software (MetaCore™ http://www.genego.com), a clear
signaling pathway associated with cell proliferation is
identified that appears to be hyper-activated in aggressive
mesothelioma tumors (Figure 9). As discussed below, in
addition to providing clear diagnostic value, this informa-
Clustering of mesothelioma tumor samples (X attribute) by clinical data (Y attribute) reveals possible epidemiological relation-ships between the various clinical featuresFigure 7
Clustering of mesothelioma tumor samples (X attribute) by clinical data (Y attribute) reveals possible epidemiological relation-
ships between the various clinical features. Some well known relationships (such as stage of disease, lymph node status, death), 
as well as some less established patterns (such as a correlation between high platelet count and recurrence) are readily 
observed in this mode of operation. The degree of the clinical event is represented on a mean centered scale, such that red 
and green indicate relatively high and low extents respectively. A subset of samples has been selected based upon the extent of 
a single trait, in this case prolonged survival time (blue).
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Clustering of samples based upon integrated clinical, experimental and molecular attributesFigure 8
Clustering of samples based upon integrated clinical, experimental and molecular attributes. In this sense, molecular-clinical 
(genotype-phenotype) associations can be readily observed. As described in the legend to Figure 7, the extent of the clinical/
molecular attribute is represented on the same normalized scale, such that red and green represent relatively high and low val-
ues respectively.
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tion is particularly useful in the design of treatment strat-
egies that may target key points within the identified
molecular network.
Clinical Diagnostics
With respect to identifying patterns (hypotheses) within
the complex clinical and molecular datasets that could be
translated into clinical diagnostic applications, we typi-
cally begin with unsupervised clustering techniques such
as hierarchical clustering as shown above in Figures 5, 6,
7. In this fashion, sample similarity with respect to
clinical, experimental and/or molecular attributes can be
assessed. Dx2Tx extends these analyses to identify clinical
and/or experimental variables that statistically correlate
with defined sample sub-groups. During this step of
hypothesis generation, Dx2Tx runs back into the database
housing all of the standardized clinical and experimental
data and identifies correlates of the selected sub-groups.
This is a highly powerful utility when operating in
unsupervised mode, and requires an intricate link
between data analysis and database content. Unsuper-
vised clustering may for example identify the degree of
Mapping molecular correlates of aggressive mesothelioma to highly curated molecular pathways can identify the underlying molecular m hanisms of the diseaseFigure 9
Mapping molecular correlates of aggressive mesothelioma to highly curated molecular pathways can identify the underlying 
molecular mechanisms of the disease. This information could be used for diagnosis, as well identification of the key steps that 
may represent intervention points in the treatment of the disease. The red arrow indicates a predicted therapeutic target 
(EGFR). Pathway mapping was generated using MetaCore™ (GeneGo, Inc., St. Joseph, MI). For more information on this path-
way mapping tool, see http://genego.com.
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molecular similarity across a cohort of patient samples,
which could identify several clearly delineated groups at
the genotype level. Running in hypothesis generation
mode, Dx2Tx then identifies statistically significant corre-
lates of these groups, and assigns clinical/experimental
features to each. When Hypothesis Generator was exe-
cuted on the 2 sample subgroups highlighted in Figure 5,
the clinical features time to recurrence (p = 0.003), T-stage
(p = 0.004), survival time (p = 0.0002) and platelet count
(p = 0.005) were returned as significant correlates of these
sub-groups. Thus, while these samples may have been ini-
tially collected in the context of a different user-defined
hypothesis, through the collection of standardized clini-
cal data in addition to the generation of multiplexed
molecular data, Dx2Tx was able to identify statistically sig-
nificant patterns (hypotheses) within the data in an unbi-
ased fashion. The user can of course decide which
hypothesis to pursue. In this example, our ability to
potentially utilize gene expression profiling to predict sur-
vival time of mesothelioma patients following surgery
based upon gene expression within the tumor would have
obvious prognostic value. Therefore, the next step would
be to test this hypothesis and determine the accuracy of a
possible diagnostic test.
Once a hypothesis has been generated, Dx2Tx identifies
samples against which the hypothesis can be tested. Cer-
tain inclusion and exclusion eligibility criteria can be con-
sidered and used to filter the content of the database to
identify subjects/samples/experiments with certain
characteristics. Dx2Tx also allows samples to be selected
based upon the extent of any attribute(s) (Figure 7). For
example, the investigator may be primarily interested in
only a subset of the sample population that displayed the
greatest and least extensive toxicity to a given drug. This is
assisted through the selection of the trait of interest and
setting the extent of the trait (i.e. by defining standard
deviations from the population mean). This feature may
be particularly important in retrospective analysis of large
clinical trial cohorts, since the outliers for a given trait can
be identified prior to sample procurement.
Once the sample population is selected, we test the
hypothesis across the series of selected samples in a 2-step
process. A subset of the samples (typically defined as a
training set) are selected (either logically or at random)
from each subgroup (for example disease versus control)
to develop a discrimination algorithm that identifies sta-
tistical correlates of the feature in question. It is worth-
while to note that Dx2Tx identifies clinical, experimental
and molecular correlates of the selected feature(s),
thereby integrating both clinical and molecular data into
the potential diagnostic algorithm. The user can exclude
any attribute from the input to the training algorithm. In
a second cross-validation test, the trained algorithm is
applied to the remainder of the samples (in retrospective
mode of operation, with known outcome), to determine
if the test could have accurately predicted the nature of the
remaining samples. The outcome of the test is plotted
using a receiver operator characteristic (ROC) curve to
determine the accuracy of the test. The ROC curve is a way
to visualize and quantify the effectiveness of a procedure
by graphing the true positive rate (Y axis) against the false
positive rate (X-axis). The area under the curve (AUC)
provides an approximation of the accuracy of the test. A
procedure with no effectiveness (AUC = 50%) would
show a random 1:1 line, indicating that for every true pos-
itive, the procedure also generated a false positive. Gener-
ally, an AUC of 90–100% is considered excellent, while an
AUC of 80–90% is good. The ideal diagnostic test would
of course identify all true positives before encountering a
false positive (AUC = 100%).
In this working example, the hypothesis generated from
analysis of unsupervised clustering of gene expression
data from mesothelioma tumors is that survival time of
patients can be predicted based upon the underlying
genomic signatures of the tumor. Thus, patients with the
shortest and longest survival time following surgery were
placed into two groups. Each group was then randomly
divided into 2 additional groups, the training set and the
test set. The discriminating clinical and molecular features
are first identified using a standard t-statistic for numerical
data and chi squared for binary (including text) data. This
test statistic is then used in a weighted voting metric [18].
Data are first converted to a respective z score in order to
normalize data of different types to a similar scale. A more
refined statistical package, which will more rigorously
integrate the binary and non-binary data, is currently in
the process of being implemented into the Dx2Tx solu-
tion. In this fashion, the experimental, molecular and
clinical attributes that statistically correlate with survival
time are first identified. In this example, no experimental
variables (i.e. those which may denote a variation in
experimental protocol or quality) were identified that cor-
related with patient survival time. The clinical parameters
platelet count and T-stage were identified as clinical corre-
lates of survival time and therefore included into the train-
ing algorithm. In addition, 157 genes were identified, the
expression of which correlated with survival time (p <
0.05). Each attribute (platelet count, stage, and the 157
individual genes) was then weighted based upon the cal-
culated t-statistic within the training group. A discrimina-
tion score (the sum of the t-statistic multiplied by the
normalized z-score for each attribute) was then calculated
for each sample within the training groups and a thresh-
old decision point (the value at which a sample is classi-
fied as neither group 1 or 2) is set halfway between the
means of the two test groups. Alternatively, a user can set
the threshold in order to maximize either sensitivity or
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specificity of the assay, or set it to a value which would
demarcate an acceptable test failure rate. In this fashion,
the end-user can set the decision point of the classification
algorithm on the side of false positives or false negatives
based upon the clinical consequence of the test result. For
example, if a positive test results in administration of a
poorly tolerated treatment, the physician would typically
error on the side of false negatives. At this time, a discrim-
ination score is calculated for the remaining test samples,
compared to the threshold decision point, and assigned a
classification. The predicted classification is then com-
pared to the actual outcome. While complicated, Dx2Tx
performs this cross-validation metric in a matter of sec-
onds. In this working example, the ROC plot generated
from the prediction of the prognosis of patients with mes-
othelioma suggests that this particular diagnostic test is
approximately 90% accurate at determining the 6 month
survival of patients following surgery as determined by
the area under the ROC curve (Figure 10). Once validated,
the classification algorithm is stored within Dx2Tx, such
that it can be applied to any future sample. Thus, through
the capture of standardized clinical, experimental and
molecular data, hypotheses can be rapidly generated and
tested, and further developed into potentially useful diag-
nostic applications. At this point, the focus may shift from
retrospective analysis to prospective studies.
From Diagnosis to Treatment
In addition to the identification of potential diagnostic
applications, we have a major focus on identifying new
treatment targets, and/or improving therapeutic strategies
involving existing treatments. Patient variation, with
respect to treatment response (efficacy and toxicity), is a
well documented phenomenon [1]. Through the captur-
ing of clinical data and pertinent samples across a large
patient population that exhibits variable treatment
A Receiver Operating Characteristic (ROC) curve showing the performance of an integrated clinical and molecular diagnostic test for predicting prognosis of pa ents with mesotheliomaFigur 10
A Receiver Operating Characteristic (ROC) curve showing the performance of an integrated clinical and molecular diagnostic 
test for predicting prognosis of patients with mesothelioma. The Area under the curve (indicative of the tests accuracy) is 
approximately 90%.
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response, retrospective statistical analysis of the integrated
clinical, experimental and molecular data could reveal the
underlying causes of this variation. For example, DNA
polymorphisms in some isoforms of the cytochrome
p450 enzymes have been associated with the variation in
the rates of metabolism of many pharmaceutical drugs
across a sample population [19]. As a result, a specific test
now exists that could be used to better determine the opti-
mal dose of some pharmaceutical treatments (Roche
Release of AmpliChip http://www.roche.com/med-cor-
2003-06-25). These so called "companion diagnostics",
which could accompany therapeutic agents and assist in
treatment decisions, are also being developed for specific
agents that display varying degrees of efficacy and toxicity
across sample populations. With the accurate capture of
longitudinal clinical data including toxicity and response
assessment, associations between clinical response and
molecular features of either the patient and/or the disease
tissue should be readily identifiable within complex retro-
spective datasets. For example, we have identified a
genomic signature within plasma cells isolated from mul-
tiple myeloma patients that correlates with tumor
response to the drug melphalan. This genomic signature is
currently being applied to additional patient samples
using cross-validation statistics as outlined above, to
determine the accuracy of this possible companion diag-
nostic application. As with most single agent treatment
regimens, drug resistance in the area of oncology
represents a significant problem in the treatment of the
disease. Therefore, pre-treatment tests could conceivably
identify the patients who would benefit the most and least
from treatment.
Our research also includes the discovery of possible early
surrogate markers of therapeutic index. This ideally
requires the collection of clinical specimens and data both
pre and post treatment. In conjunction with the treatment
of cell lines in culture and molecular analysis of livers and
kidneys from treated mice, early biomarkers of efficacy
and toxicity have been identified in association with sev-
eral treatment regimens. If these biomarkers of response
can be validated in retrospective patients, they could be
written into future clinical studies to provide an early
indication of therapeutic effect. These biomarkers may
ultimately be used as surrogate markers to determine
discontinuation or modification of protocols to maximize
therapeutic index in prospective trials.
There are currently a number of drugs in development, in
clinical trials or that have recently received FDA approval
that target specific molecular aberrations [20-23]. Unlike
cytotoxic chemotherapies, molecularly targeted
therapeutics often display a high degree of specificity
against the selected target. Based upon the specificity of
these drugs to defined proteins, it is envisioned that
molecular-based diagnostics will naturally accompany
these agents to identify the patient sub-population who
will benefit from treatment. Because of the inherent
genomic instability of cancer, combinations of these
molecularly targeted drugs will almost certainly be
required to ultimately treat the disease. Indeed, mathe-
matical models of adaptive microevolution of the cancer
cell suggest that a multi-modality treatment strategy that
targets at least five individual molecular targets simultane-
ously will be required to minimize the chance of a single
cell within the tumor acquiring resistance to each agent
[24]. As part of our research effort, we are attempting to
identify the optimal multi-modality targeting strategies to
treat specific tumor types based upon their molecular
makeup. For these reasons, we have incorporated a drug-
target database that is regularly updated to include molec-
ularly targeted agents as they are publicly disclosed. Dur-
ing analysis, we can filter the datasets to only include
genes/proteins against which drugs have already been
developed. For example, we can substitute the drug-target
list as a filter in place of the known secreted or plasma
membrane proteins discussed in relation to Figure 4.
When performing this function on the mesothelioma
dataset, epidermal growth factor receptor (EGFR) inhibi-
tors in combination with eniluracil and topoisomerase II
inhibitors are identified as a possible combination treat-
ment for mesothelioma based upon relatively high
expression of their molecular targets EGFR, Dihydropyri-
midine dehydrogenase and topoisomerase II respectively.
Such hypotheses obviously require testing in a relevant
preclinical model of the disease (see below). Nonetheless,
because the corresponding drugs have already been devel-
oped, this is a readily testable hypothesis assuming the
investigator can gain access to the therapeutic agent. As
discussed below, however, we do not believe that expres-
sion levels of the molecular target alone are necessarily
sufficient to predict drug efficacy.
The FDA approval process of the EGFR inhibitor Iressa has
received a great deal of attention [25]. Recently, it was
shown that lung carcinomas from a subset of patients that
possess activating mutations in the EGFR are most respon-
sive to Iressa [26,27]. This raises an important concept we
have been pursuing for some time; namely that diagnostic
tests need to address activity of the target(s) rather than
merely expression levels. Since an active molecule can
often shut down its own expression, while conversely,
hypo-active targets may consequently be over-expressed,
this biological phenomenon of negative feedback often
results in inverse expression-activity relationships (CPW,
unpublished observations). Hence, in combination with
gene silencing technologies (such as RNA interference)
that mimic a selective drugs action, we are identifying the
down-stream genomic and proteomic consequences of
target gene disruption for the purpose of identifying
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biomarkers that could be used to assess target activity. We
believe that rather than using expression levels of the tar-
get molecule alone as a rudimentary diagnostic test, this
more sophisticated approach may yield greater success in
attempting to predict the optimal treatment strategies
based upon a molecular profile.
In addition to pursuing existing drug targets, we are also
attempting to identify novel targets that may warrant
future drug discovery efforts. We typically attempt to vali-
date only candidate genes/proteins that have or are pre-
dicted to have "drugable" characteristics. To determine
whether a potential target is drugable, we are currently
using some relatively simple criteria based upon the
classes of drug targets that have been actively pursued by
pharmaceutical/biotech companies to date. For example,
we have annotated the publicly available drug targets
described above using gene ontology and literature min-
ing tools within Dx2Tx [9], and identified several recur-
ring features of these targets (such as kinases,
phosphatases, G-protein coupled receptors, etc). Any
gene/protein identified with the same annotation is "dru-
gable" by simple association. We also identify genes/pro-
teins that co-cluster with genes/proteins with drugable
features, since as described above co-expressed genes/pro-
teins often share similar functionality. Future develop-
ments will include sequence, domain and structural-
based predictions of drugable characteristics, but it
remains to be seen if this selective approach will lead to
accelerated clinical application in the future. Nonetheless,
using the combined content and analytical power of
Dx2Tx we can sequentially filter data in an attempt to
identify specific targets for the disease in question and
condense our target candidates further to identify those
with the greatest potential for drug development.
Preclinical Models of Disease
The majority of the preceding discussion has focused on
the identification of molecular correlates of disease, and
identifying those that may represent diagnostic biomark-
ers and/or treatment targets for intervention. A large pro-
portion of our translational research effort is dedicated to
functional validation, where through various means, the
expression and/or activity of the target are modified and
the functional consequences addressed. While determin-
ing the function of a diagnostic biomarker is not
necessary, the functional consequence of target gene/pro-
tein disruption is essential when establishing the true
therapeutic value of a potential target. An ideal
therapeutic target would be one that is causative of the
disease, and inhibitors against which thus cause disease
regression. The following discussion will focus on a high-
throughput means by which we assess the functional sig-
nificance of target gene/protein disruption in murine
models of various human malignancies.
There are a variety of approaches one can take to interfere
with gene/protein expression and/or function with the
purpose of demonstrating a definitive role in a biological
process [28]. These include the use of pharmacological
agents, antibodies and/or interfering mutants. However,
these approaches require reagent access and/or some in-
depth knowledge about the gene/protein in question.
These approaches are also relatively low throughput and
expensive, and can result in a significant bottleneck effect
as potential targets are identified during the translational
research effort. Antisense technologies represent an excel-
lent approach to determine gene function, and are readily
integrated into gene/protein discovery programs due to
the wealth of gene/protein sequence information now
available [29,30]. In this regard, the field of RNA interfer-
ence has emerged as a highly specific and relatively simple
way to disrupt genes [31]. RNA interference (RNAi) is a
conserved phenomenon, whereby long double stranded
RNA (dsRNA) is processed into small 21–23 nucleotide
dsRNA fragments, termed short interfering RNA (siRNA)
[32]. These fragments then target and degrade highly
homologous RNA gene transcripts, thereby inhibiting
gene expression in a sequence-specific manner. RNAi is
thought to function to maintain genomic stability,
regulate cellular gene expression, and defend cells against
viral infection [33,34].
We have developed an avian retroviral vector that can
deliver siRNA to cells expressing the viral receptor (TVA)
[35]. TVA expression can be directed to specific cells in
vitro through exogenous transfection/infection, or in vivo
through transgenic technology [36]. This system was
developed to allow us to target the delivery of gene-spe-
cific siRNA to tumor and/or endothelial cells in vivo, such
that the effect that target gene disruption has on tumor
growth, metastasis and angiogenesis can be directly
assessed. As discussed above, we typically target genes/
proteins that we predict to have "drugable" characteristics,
and in a sense this retroviral-siRNA approach mimics the
optimal molecularly-targeted drug due to its targeted
delivery and exceptional degree of gene specificity. In
addition, these avian retroviruses do not replicate within
mammalian cells and as such cells can be infected multi-
ple times with vectors targeting multiple genes. This sys-
tem therefore allows us to investigate the functional
consequences of combinational targeting strategies.
Because of the particular cloning strategies we have incor-
porated, it takes only six weeks from the discovery of a
potential target gene to the point of assessing functional
consequences of gene disruption in a relevant preclinical
model of the disease. Because of the efficiency of the sys-
tem, we are able to assess multiple targets simultaneously.
For example, we are currently evaluating 19 targets in var-
ious combinations that have been predicted to display
optimal efficacy in murine models of mesothelioma,
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pancreatic cancer, colorectal cancer and multiple mye-
loma. Thus, by introducing a systematic approach to tar-
get validation, we have limited the bottleneck between
target discovery and functional validation.
Improved murine models that depict specific features of
the human disease in question are essential to validate the
in vivo significance of experimental findings in a relevant
preclinical setting. We particularly focus on the develop-
ment of orthotopic xenograft models, in which human
tumor cells are implanted into their corresponding site of
origin within an immune compromised mouse. In this
fashion, human tumors form in the tissue site of origin
that more closely resemble the human counterpart with
respect to biological behavior. These orthotopic models
better recapitulate the various stages of tumor progression
and more accurately reflect responsiveness to various ther-
apeutic intervention strategies [37]. Coupled with in vitro
and in vivo delivery of siRNA against multiple target genes,
these preclinical models readily allow us to evaluate the
requirement of proposed target genes in tumor progres-
sion. Through these studies, we are beginning to identify
the optimal combination targeting strategies that may
lead to the eventual treatment of aggressive cancers.
Moving from Retrospective Analysis to 
Prospective Clinical Trials
In the vast majority of cases in which molecular data is
being correlated with clinical events, a hypothesis-driven
inquiry is tested against archived clinically documented
specimens. The majority of these trials are asking either a
classification question (i.e. what profile sets this tumor
apart from other tumors), a prognostication pattern (what
group of genomic/proteomic patterns will predict time to
progression or time to death), early detection (how is this
tumor different from its "cell of origin" at the earliest time
point recognizable such that a genomic/proteomic pat-
tern could predict the development of malignancy in a
high risk population), or response to therapy (is there a de
novo set of genomic/proteomic parameters which predict
either response or resistance to a given therapy). For clas-
sification phenomena, the investigator must currently rely
on pathologic differences to stratify tumors into clusters
which, upon genomic/proteomic analysis, have consist-
ent and congruent distinguishing features. This is
probably the easiest of analyses and relies mainly on
established architectural and morphologic differences
between tumors instead of clinical behavior and
endpoints. Nevertheless, as with all discovery test-sets,
validation prospectively must be performed in order to
test the accuracy of the classification algorithms. This
requires prospective application of the algorithm to
blinded samples, and comparing the predicted outcome
with the actual observed pathology.
For the early detection, prognostication, and prediction of
therapeutic response, one must link potential diagnostic
tests to newly developing trials to allow validation of the
established hypothesis. Before undertaking such an effort,
however, the investigator must realize that the data were
typically derived from a set of patients within a particular
treatment regimen. For example, the patients presented in
this article were characterized as having specimen pro-
curement prior to definitive cytoreductive surgery fol-
lowed by adjuvant therapy, and therefore a prospective
trial which conforms to this treatment regimen should
ideally be designed to avoid confounding variables. For
the validation of diagnostics that predict time to recur-
rence or survival following treatment, a phase II trial of
surgery and/or postoperative adjuvant therapy could be
designed in which samples are harvested at the time of
surgery. The diagnostic test would then be performed on
the clinical specimen to obtain a prediction of patient
outcome, and the patients' clinical course followed to see
if there is prospective validation of the test. These analy-
ses, however, must be performed in patient groups not
weighted towards either high or low risk patients, and
indeed, some stratification of clinical parameters should
be specified at the outset in order to make reasonable
comparisons. This is especially true if the molecular data
is to be validated as part of a Phase III randomized trial
comparing two treatment regimens after surgery. As the
content of Dx2Tx expands to include clinical trial data,
analysis can be performed on only those patients that con-
form to specified clinical parameters. Therefore, with the
complete and standardized collection of clinical data
from a large population of patients receiving various treat-
ment regimens both on and off of protocol, established
hypotheses can be further tested on additional retrospec-
tive subjects; in a sense a virtual trial that begins to more
closely resemble the carefully controlled prospective clin-
ical trial.
The ideal clinical trials addressing the validity of molecu-
lar data to predict a clinical parameter are those involving
patients with no prior diagnosis or treatments, who sub-
sequently receive a single therapeutic regimen. Preferably,
both pre- and post-treatment specimens are obtained
from these patients. Such a pure trial could, for example,
test whether a predefined genomic/proteomic pattern
could predict a poor outcome despite favorable clinical
parameters. Trials of patients receiving initial chemother-
apy could also help to define the fidelity of the omics
technologies for the prediction of chemosensitivity. These
hypotheses may have been derived from a retrospective
set of patients receiving the same chemotherapy or tar-
geted therapy for which outcomes were known, or from
the in vitro discovery of genomic/proteomic patterns
defined in cell lines treated with the corresponding
agent(s).
Journal of Translational Medicine 2004, 2:35 http://www.translational-medicine.com/content/2/1/35
Page 21 of 22
(page number not for citation purposes)
Early detection clinical trials using genomic and/or pro-
teomic technologies will typically take the longest to vali-
date. After the discovery of proteins as candidate markers
from analyses of serum, urine, or other fluids in patients
with early stage malignancies compared to the appropri-
ate high risk group, cohorts of high risk individuals (e.g.
asbestos exposed or tobacco smokers) must be identified
who are willing to have collections of the appropriate
specimens longitudinally at given intervals. Moreover, in
initial trials of these markers, the investigator must define
at what time to disclose the value of the measured biomar-
ker. One possibility would be to allow the prospective
clinical trial to reach a certain endpoint (i.e. a certain
number of cancers occur in the cohort which are detected
by the standard of care radiographic or physical examina-
tion) and then reveal the results of the marker to see
whether there is predictive value. Another way would be
to define the value of the marker at follow-up intervals
during the course of the trial and, in the face of radio-
graphic or physical findings, initiate an invasive workup
to "find" the predicted cancer. It is generally agreed that,
although a two stage validation effort takes longer (i.e.
blinded values for the marker in question until comple-
tion of the study followed by a study with invasive or
semi-invasive investigations based on fluctuations or
absolute levels of the marker), such a model is currently
preferred.
With respect to novel treatment strategies predicted from
retrospective analysis and/or through the preclinical stud-
ies defined above, the next logical step is to attempt to val-
idate the retrospective data which initially pointed the
investigators to these potential treatment options. If the
new therapy has never been used in humans before, it is
important to define the maximum tolerated dose of the
treatment. This is defined as the dose at which, in a Phase
I clinical trial, a defined fraction (typically one third) of
the patient cohort develop dose limiting toxicity. Once
the dose or treatment strategy is found to be acceptable, a
Phase II trial is designed to provide a measure of the activ-
ity of the agent(s) and to begin to define whether there is
any benefit of the regimen in certain patient cohorts. The
use of tools such as Dx2Tx could be invaluable in the
future tracking and analysis of such trials, especially if
samples are prospectively harvested at various times pre
and post treatment. For example, in the Phase I/II trial,
genomic/proteomic correlates of clinical toxicity could be
readily identified by melding the clinical data with "omic"
data from the patients who have undue toxicity. Molecu-
lar pathways that intuitively result in toxicity could be
identified which could possibly be abrogated with
another agent. With respect to determination of therapeu-
tic efficacy, our present means of defining "clinical corre-
lates of response" is essentially a "best guess" or subjective
prediction of what clinical markers may indicate that the
new agent is yielding a therapeutic effect. A more objective
measure of downstream events resulting from an effica-
cious agent would result from analysis of the molecular
data in tandem with clinical information for the respond-
ers compared to the non-responders. Dx2Tx would be
able to then define the most important markers of
response, both clinical and molecular, which could then
be validated in a Phase III trial assessing agent efficacy.
End Use
It is unknown when an integrated clinical/molecular eval-
uation of the suspected or afflicted cancer patient will be
of use to the end user, the practicing physician. Certainly,
many of the same arguments that are used for and against
"genetic testing" in other diseases may be used for such a
global approach to oncology. There is no doubt however,
the ability to define clinical behavior in a more efficacious
and predictive manner, other than the archaic prognostic
indicators which we use today, will help clinicians initiate
and/or alter treatment course earlier and guide clinicians
toward informed discussions with their patients in order
to make treatment and/or surveillance decisions. If indeed
the fidelity of combinatorial molecular and clinical med-
icine proves to be satisfactory, we may then be able to
spare patients unnecessary treatment interventions which
are currently doomed to failure. Moreover, the medical
oncologist will be able to choose the correct cytotoxic
and/or targeted therapy based on a global clinical-molec-
ular snap-shot, which should translate into more favora-
ble health economic policies and patient outcomes.
Conclusions
Throughout this review, we have highlighted the impor-
tance of designing research protocols involving human
subjects that permit the collection of not only clinical
specimens, but also extensive standardized clinical data in
a longitudinal fashion. Through the merging of clinical
and molecular data, non-biased patterns can be discov-
ered that could translate into novel diagnostic and/or
treatment opportunities. We have introduced a methodi-
cal approach for archiving and mining these seemingly
disparate data sources that we believe can accelerate the
translational research discovery pipeline. While there are
clearly improvements to be made in the systematic collec-
tion of accurate and nationally standardized clinical data,
we believe the integration of medical informatics and the
molecular technologies can convert the once visionary
concept of molecular-based medicine into a present
reality.
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